Expanding the detectable HLA peptide repertoire using electron-transfer/ higher-energy collision dissociation (EThcD)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 12, 2014, Pages 4507-4512

  Mommen, Geert P M ^a,b,c   Frese, Christian K ^b,c   Meiring, Hugo D ^a   Gaans van Den Brink, Jacquelinevan ^d   De Jong, Ad P J M ^a   Van Els, Cécile A C M ^d   Heck, Albert J R ^b,c  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Binding motif; Electron transfer dissociation; Human leukocyte antigen class I; Major histocompatibility complex; Phosphorylation

Indexed keywords

ASPARTIC ACID; HLA ANTIGEN CLASS 1; METHIONINE; SERINE; THREONINE;

ALLELE; ANALYTIC METHOD; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYCLIZATION; DEAMINATION; ELECTRON TRANSFER HIGHER ENERGY COLLISION DISSOCIATION; HEALTH STATUS; HUMAN; HUMAN CELL; OXIDATION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING;

BINDING MOTIF; ELECTRON-TRANSFER DISSOCIATION; HUMAN LEUKOCYTE ANTIGEN CLASS I; MAJOR HISTOCOMPATIBILITY COMPLEX; PHOSPHORYLATION;

ALLELES; B-LYMPHOCYTES; CELL LINE; CHROMATOGRAPHY, LIQUID; ELECTRON TRANSPORT; HLA ANTIGENS; HUMANS; PEPTIDES; TANDEM MASS SPECTROMETRY;

EID: 84896980006     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321458111     Document Type: Article

References (37)

1. Parkin J, Cohen B (2001) An overview of the immune system. Lancet 357(9270):1777-1789. (Pubitemid 32524226)
2. Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11(12):823-836.
3. Rammensee HG, Friede T, Stevanoviíc S (1995) MHC ligands and peptide motifs: First listing. Immunogenetics 41(4):178-228.
4. Kessler JH, Melief CJ (2007) Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21(9):1859-1874. (Pubitemid 47299958)
5. Ovsyannikova IG, Johnson KL, Bergen HR, 3rd, Poland GA (2007) Mass spectrometry and peptide-based vaccine development. Clin Pharmacol Ther 82(6):644-652. (Pubitemid 350114820)
6. Mester G, Hoffmann V, Stevanović S (2011) Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci 68(9):1521-1532.
7. Chi A, et al. (2007) Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry. Proc Natl Acad Sci USA 104(7):2193-2198. (Pubitemid 46391374)
8. Frese CK, et al. (2011) Improved peptide identification by targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap Velos. J Proteome Res 10(5):2377-2388.
9. Frese CK, et al. (2012) Toward full peptide sequence coverage by dual fragmentation combining electron-transfer and higher-energy collision dissociation tandem mass spectrometry. Anal Chem 84(22):9668-9673.
10. Frese CK, et al. (2013) Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD). J Proteome Res 12(3):1520-1525.
11. Hunt DF, et al. (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049):1261-1263.
12. Käll L, Canterbury JD, Weston J, Noble WS, MacCoss MJ (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4(11):923-925. (Pubitemid 350042380)
13. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4(3):207-214. (Pubitemid 46358868)
14. Lundegaard C, et al. (2008) NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36(Web Server issue):W509-12.
15. Zhang H, Lundegaard C, Nielsen M (2009) Pan-specific MHC class I predictors: A benchmark of HLA class I pan-specific prediction methods. Bioinformatics 25(1):83-89.
16. Hassan C, et al. (2013) The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 12(7):1829-1843.
17. Ben Dror L, Barnea E, Beer I, Mann M, Admon A (2010) The HLA-B*2705 peptidome. Arthritis Rheum 62(2):420-429.
18. Granados DP, et al. (2012) MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood 119(26):e181-e191.
19. Altelaar AF, et al. (2012) Database independent proteomics analysis of the ostrich and human proteome. Proc Natl Acad Sci USA 109(2):407-412.
20. Yewdell JW (2006) Confronting complexity: Real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25(4):533-543.
21. Burrows SR, Rossjohn J, McCluskey J (2006) Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 27(1):11-16. (Pubitemid 43083559)
22. Petersen J, Purcell AW, Rossjohn J (2009) Post-translationally modified T cell epitopes: Immune recognition and immunotherapy. J Mol Med (Berl) 87(11):1045-1051.
23. Skipper JC, et al. (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183(2):527-534. (Pubitemid 26059516)
24. Cobbold M, et al. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5(203):203ra125.
25. Zarling AL, et al. (2006) Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci USA 103(40):14889-14894. (Pubitemid 44527824)
26. Meyer VS, et al. (2009) Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res 8(7):3666-3674.
27. Meadows L, et al. (1997) The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6(3):273-281. (Pubitemid 27148594)
28. Pierce RA, et al. (1999) Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 163(12):6360-6364.
29. Ostrov DA, et al. (2012) Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 109(25):9959-9964.
30. Nagaraj N, et al. (2011) Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 7:548.
31. Hickman HD, et al. (2004) Toward a definition of self: Proteomic evaluation of the class I peptide repertoire. J Immunol 172(5):2944-2952. (Pubitemid 38263681)
32. Escobar H, et al. (2008) Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs. J Immunol 181(7):4874-4882.
33. Hearn A, York IA, Rock KL (2009) The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol 183(9):5526-5536.
34. Lorente E, et al. (2013) Diversity of natural self-derived ligands presented by different HLA class I molecules in transporter antigen processing-deficient cells. PLoS ONE 8(3):e59118.
35. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101(12):4175-4179. (Pubitemid 38405902)
36. Kittlesen DJ, et al. (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J Immunol 160(5):2099-2106. (Pubitemid 28119887)
37. van Els CA, et al. (2000) A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur J Immunol 30(4):1172-1181.